Emcdonald on DSK2BSOYB1PROD with NOTICES

14976 Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 

Quality Measures Workgroup. ONC 

intends to make background material 

available to the public no later than two 

(2) business days prior to the meeting. 

If ONC is unable to post the background 

material on its Web site prior to the 

meeting, it will be made publicly 

available at the location of the advisory 

committee meeting, and the background 

material will be posted on ONC’s Web 

site after the meeting, at http:// 

healthit.hhs.gov. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 8, 2011. Oral 

comments from the public will be 

scheduled between approximately 3:30 

and 4:30 p.m. Time allotted for each 

presentation is limited to three minutes. 

If the number of speakers requesting to 

comment is greater than can be 

reasonably accommodated during the 

scheduled open public hearing session, 

ONC will take written comments after 

the meeting until close of business. 

Persons attending ONC’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

ONC welcomes the attendance of the 

public at its advisory committee 

meetings. Seating is limited at the 

location, and ONC will make every 

effort to accommodate persons with 

physical disabilities or special needs. If 

you require special accommodations 

due to a disability, please contact Judy 

Sparrow at least seven (7) days in 

advance of the meeting. 

ONC is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://healthit.hhs.gov for procedures 

on public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act 

(Pub. L. 92–463, 5 U.S.C., App. 2). 

Dated: March 11, 2011. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. 2011–6407 Filed 3–17–11; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

HIT Standards Committee Advisory 

Meeting; Notice of Meeting 

AGENCY: Office of the National 

Coordinator for Health Information 

Technology, HHS. 

ACTION: Notice of meeting. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Office of the National Coordinator 

for Health Information Technology 

(ONC). The meeting will be open to the 

public. 

Name of Committee: HIT Standards 

Committee. 

General Function of the Committee: 

To provide recommendations to the 

National Coordinator on standards, 

implementation specifications, and 

certification criteria for the electronic 

exchange and use of health information 

for purposes of adoption, consistent 

with the implementation of the Federal 

Health IT Strategic Plan, and in 

accordance with policies developed by 

the HIT Policy Committee. 

Date and Time: The meeting will be 

held on April 20, 2011, from 9 a.m. to 

3 p.m./Eastern Time. 

Location: Renaissance Dupont Circle 

Hotel, 1143 New Hampshire Avenue, 

NW., Washington, DC. For up-to-date 

information, go to the ONC Web site, 

http://healthit.hhs.gov. 

Contact Person: Judy Sparrow, Office 

of the National Coordinator, HHS, 330 C 

Street, SW., Washington, DC 20201, 

202–205–4528, Fax: 202–690–6079, 

e-mail: judy.sparrow@hhs.gov. Please 

call the contact person for up-to-date 

information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Agenda: The committee will hear 

reports from its workgroups, including 

the Clinical Operations, Vocabulary 

Task Force, Clinical Quality, 

Implementation, and Enrollment 

Workgroups. ONC intends to make 

background material available to the 

public no later than two (2) business 

days prior to the meeting. If ONC is 

unable to post the background material 

on its Web site prior to the meeting, it 

will be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on ONC’s Web site after 

the meeting, at http://healthit.hhs.gov. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 15, 2011. Oral 

comments from the public will be 

scheduled between approximately 2 and 

3 p.m./Eastern Time. Time allotted for 

each presentation will be limited to 

three minutes each. If the number of 

speakers requesting to comment is 

greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, ONC will 

take written comments after the meeting 

until close of business. 

Persons attending ONC’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

ONC welcomes the attendance of the 

public at its advisory committee 

meetings. Seating is limited at the 

location, and ONC will make every 

effort to accommodate persons with 

physical disabilities or special needs. If 

you require special accommodations 

due to a disability, please contact Judy 

Sparrow at least seven (7) days in 

advance of the meeting. 

ONC is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://healthit.hhs.gov for procedures 

on public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act 

(Pub. L. 92–463, 5 U.S.C., App. 2). 

Dated: March 11, 2011. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. 2011–6408 Filed 3–17–11; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Decision To Evaluate a Petition To 

Designate a Class of Employees From 

Mathieson Chemical Co., Pasadena, 

TX, To Be Included in the Special 

Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice as required 

by 42 CFR 83.12(e) of a decision to 

evaluate a petition to designate a class 

of employees from Mathieson Chemical 

Co., Pasadena, Texas, to be included in 

the Special Exposure Cohort under the 

Energy Employees Occupational Illness 

Compensation Program Act of 2000. The 

initial proposed definition for the class 

being evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Mathieson Chemical Co. 

Location: Pasadena, Texas. 

Job Titles and/or Job Duties: All 

employees. 

Period of Employment: 1951 through 

October 2009. 

Emcdonald on DSK2BSOYB1PROD with NOTICES

Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 14977 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by e-mail to 

DCAS@CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2011–6369 Filed 3–17–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 76, FR 1167, dated 

January 7, 2011) is amended to reflect 

the reorganization of the National 

Center for Emerging and Zoonotic 

Infectious Diseases, Office of Infectious 

Diseases, Centers for Disease Control 

and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in their entirety the titles and 

functional statements for the Division of 

Healthcare Quality Promotion (CVLD) 

and insert the following: 

Division of Healthcare Quality 

Promotion (CVLD). The mission of the 

Division of Healthcare Quality 

Promotion (DHQP) is to protect patients; 

protect healthcare personnel; and 

promote safety, quality, and value in 

both national and international 

healthcare delivery systems. In carrying 

out its mission, DHQP: (1) Measures, 

validates, interprets, and responds to 

data relevant to healthcare-associated 

infections (HAI); antimicrobial 

resistance; adverse drug events; blood, 

organ and tissue safety; and 

immunization safety; and other related 

adverse events or medical errors in 

healthcare affecting patients and 

healthcare personnel; (2) investigates 

and responds to emerging infections and 

related adverse events among patients 

and healthcare personnel; (3) develops 

and maintains the National Healthcare 

Safety Network (NHSN), a tool for 

monitoring healthcare-associated 

infections, measuring healthcare 

outcomes and processes, and 

monitoring healthcare worker 

vaccination and selected health 

measures in healthcare facilities; (4) 

assesses rates of infections caused by 

resistant-bacteria in the U.S. through 

active surveillance, review of national 

healthcare data sets, and laboratory 

surveillance programs; (5) conducts 

epidemiologic, and basic and applied 

laboratory research to identify new 

strategies to prevent infections/ 

antimicrobial resistance, and related 

adverse events or medical errors, 

especially those associated with medical 

or surgical procedures, indwelling 

medical devices, contaminated 

products, dialysis, and water; (6) 

collaborates with academic and public 

health partners to design, develop, and 

evaluate the efficacy of interventions for 

preventing infections and reducing 

antimicrobial resistance, and related 

adverse events or medical errors; (7) 

develops and disseminates evidencebased guidelines and recommendations 

to prevent and control HAT, 

antimicrobial resistance, and related 

adverse events or medical errors; (8) 

promotes the nationwide 

implementation of Healthcare Infection 

Control Practices Advisory Committee 

(HICPAC) recommendations and other 

evidence-based interventions to prevent 

HAI, antimicrobial resistance, and 

related adverse events or medical errors 

among patients and healthcare 

personnel; (9) evaluates the impact of 

evidence-based recommendations and 

interventions across the spectrum of 

healthcare delivery sites; (10) develops, 

implements, and evaluates the 

effectiveness of interventions to prevent 

transmission of healthcare-associated 

human immunodeficiency virus (HIV) 

and other bloodborne pathogen, 

infections; (11) serves as the National 

Reference Laboratory for the 

identification and antimicrobial 

susceptibility testing of staphylococci, 

anaerobic bacteria, non-tuberculous 

mycobacterial, and those gram-negative 

bacilli causing healthcare associated 

infections; (12) serves as the technical 

reference laboratory for detection and 

characterization of other pathogens 

related to healthcare; and for 

characterizing the contribution of the 

healthcare environment to HAI; (13) 

coordinates guidance and research 

related to infection control across the 

agency and with national and 

international partners; (14) monitors 

vaccine safety and conducts research to 

evaluate the safety of available and new 

vaccines; (15) promotes the integration 

of the healthcare delivery system in 

federal/state/local public health 

preparedness planning; (16) trains 

Epidemic Intelligence Service Officers 

and other trainees; (17) coordinates 

antimicrobial resistance activities at 

CDC; (18) works in a national leadership 

capacity with public and private 

organizations to enhance antimicrobial 

resistance prevention and control, 

surveillance and response, and applied 

research; (19) coordinates blood, organ, 

and other tissue safety at CDC; and (20) 

provides expertise arid assistance to 

HHS and other Federal agencies on 

efforts and activities related to health 

reform. 

Office of the Director (CVLD1). (1) 

Manages, directs, and coordinates the 

activities of the DHQP; (2) provides 

leadership and guidance on policy and 

communications/media; (3) works with 

Federal agencies, CDC’s Office of 

Prevention through Healthcare, and 

other partners on activities related to 

Health Reform; (4) coordinates state and 

local activities to monitor and prevent 

HAI; (5) provides liaison with other 

governmental agencies, international 

organizations, and other outside groups; 

(6) coordinates, in collaboration with 

the appropriate CIO and CDC 

components, global health activities 

relating to the prevention of healthcareassociated infections/antimicrobial 

resistance, and related adverse events or 

medical errors; (7) coordinates 

activities, guidance, emergency 

response, and research related to 

infection control in healthcare settings 

across the agency and with national and 

international partners; (8) works with 

other federal agencies, state 

governments, medical societies, and 

other public and private organizations 

to promote collaboration and to 

integrate healthcare preparedness in 

federal/state/local public health 

preparedness planning; (9) oversees the 

coordination of antimicrobial resistance 

activities at CDC; (10) represents CDC as 

co-chair of the federal Interagency Task 

Force on Antimicrobial Resistance; (11) 

coordinates with other agencies, state 

governments, medical societies, and 

other public and private organizations 

to enhance antimicrobial resistance 

prevention and control, surveillance 

and response, and applied research; (12) 

leads CDC’s activities on blood, organ, 

and other tissue safety; (13) represents 

CDC on the Advisory Committee on 

Blood Safety and Availability and the 

Advisory Committee on Organ 

Transplantation; (14) works with other 

federal agencies, state governments, and